CASTOR

POLLUX & CASTOR analysis: MRD- with dara-combination regimens 1:44
POLLUX & CASTOR analysis: MRD- with dara-combination regimens
Sagar Lonial • 11 Mar 2021
CD38: a promising target for multiple myeloma antibody therapy 4:52
CD38: a promising target for multiple myeloma antibody therapy
Saad Usmani • 5 Oct 2020
The next five years of multiple myeloma treatment 1:39
The next five years of multiple myeloma treatment
Graham Jackson • 2 Oct 2020
Therapeutic options for hard to treat R/R myeloma 5:52
Therapeutic options for hard to treat R/R myeloma
Mohamad Mohty • 31 Aug 2020
Cytogenetic risk & the impact of daratumumab in myeloma 4:13
Cytogenetic risk & the impact of daratumumab in myeloma
Luciano Costa • 15 Jun 2020
8:25
The definitive guide to multiple myeloma at ASH 2018: part I
Mohamad Mohty et al.
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma 2:21
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Maria-Victoria Mateos • 5 Oct 2018
Carfilzomib for relapsed multiple myeloma: clinical trial updates 3:08
Carfilzomib for relapsed multiple myeloma: clinical trial updates
Katja Weisel • 14 Jun 2018
The importance of MRD status in MM 1:22
The importance of MRD status in MM
Niels van de Donk • 14 Jun 2018
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM 1:54
CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
Katja Weisel • 9 Dec 2017
Promising results for daratumumab in the front line setting 2:42
Promising results for daratumumab in the front line setting
Philippe Moreau
Unprecedented clinical trial results for MM 3:22
Unprecedented clinical trial results for MM
Alberto Rocci • 6 Oct 2017
How effective are monoclonal antibodies at improving overall survival? 3:34
How effective are monoclonal antibodies at improving overall survival?
Philippe Moreau • 21 Apr 2017
Effective antibody therapy and updates from the POLLUX and CASTOR trials 1:56
Effective antibody therapy and updates from the POLLUX and CASTOR trials
Meletios Dimopoulos • 21 Apr 2017
Daratumumab in the treatment of multiple myeloma 2:13
Daratumumab in the treatment of multiple myeloma
Paul Richardson • 27 Mar 2017
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma? 3:19
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Nikhil Munshi • 21 Apr 2017
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals